Circassia Group PLC news
Circassia Pharmaceuticals plc, (“Circassia” or “the Company”; LSE: CIR) announces that the Board has concluded that it is in the best interests of the Company to terminate the development and commercialisation agreement between the Company and AstraZeneca UK Limited, a subsidiary of AstraZeneca plc (LSE/STO/NYSE: AZN) (AstraZeneca) for the U.S. commercial rights to Tudorza® and Duaklir® and tr
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US launch of Duaklir® for the maintenance treatment of chronic obstructive pulmonary disease (COPD) at the American College of Chest Physicians’ CHEST Annual Meeting 2019, which is currently ongoing in New Orleans, LA.
Duaklir® is a fixed-dose LAMA / LABA combination of the long-acting musca
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, today announces the appointment of Jonathan Emms to the newly-created role of Chief Operating Officer (COO). As COO he will further strengthen Circassia’s commercial focus and lead the Company’s global commercial strategy and operational management. He will also join the Company’s Board as an Executive Dir
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of the American Medical Association*.
The ASCENT study was conducted in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) and cardiovascular disease and / or significant cardiovascular ri
Oxford, UK – 8 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of the American Medical Association*.
The ASCENT study was conducted in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) and cardiovascula
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration (FDA) has approved Duaklir® for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Duaklir® is a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide (400 mcg) and long-acting beta-agonist (LABA) formoterol fumara
Oxford, UK – 1 April 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration (FDA) has approved Duaklir® for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Duaklir® is a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide (400 mcg) and
Data showing reduction in COPD exacerbations and no increase in major cardiovascular events vs placebo added to label –
– Tudorza® is the only product in its class with these data in the label
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration (FDA)
Oxford, UK – 29 March 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration (FDA) has approved Tudorza®’s supplemental New Drug Application (sNDA) for the inclusion of unique new clinical data in the product’s label. Tudorza® is indicated for the maintenance treatment of chronic obstruc
Oxford, UK – 11 December 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces it has issued a notice of option exercise to AstraZeneca to acquire the full US commercial rights to Tudorza® (aclidinium). Circassia currently promotes the COPD treatment in the United States under a profit share arrangement established by the two companies i